造血干细胞微移植治疗的现状与挑战  

Microtransplantation of hematopoietic stem cells:current status and challenges

作　　者：杨园园 李菲[1] YANG Yuan-yuan;LI Fei(Department of Hematology,the First Affiliated Hospital of Nanchang University,Clinical Research Center for Hematologic Disease of Jiangxi Province,Institute of Lymphoma Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第一附属医院血液科、江西省血液病临床医学研究中心、南昌大学淋巴肿瘤疾病研究所,江西南昌330006

出　　处：《中国实用内科杂志》2024年第4期280-285,共6页Chinese Journal of Practical Internal Medicine

基　　金：江西省科技创新基地计划:江西省血液病临床医学研究中心(20212BCG74001);江西省科技合作专项项目(20212BDH80024);江西省主要学科学术和技术带头人培养项目(20213BCJ22016)。

摘　　要：造血干细胞微移植(MST)是在尽量避免损害受者免疫功能的前提下,将化疗、异基因造血干细胞移植(alloHSCT)同细胞免疫治疗相结合的一种新型移植术。MST通过输注供者干细胞使供体植入形成微嵌合体,发挥抗肿瘤效应并避免发生移植物抗宿主病(GVHD)。MST被用于血液恶性肿瘤治疗,显著提高疾病完全缓解(CR)率、总生存(OS)率和疾病无进展生存(DFS)率,促进造血恢复、降低感染风险、避免GVHD发生。为使MST更好应用于临床,文章就MST作用机制、临床应用现状及目前所面临挑战进行综述。Hematopoietic stem cell microtransplantation(MST)is a new type of transplantation surgery that combines chemotherapy,allogeneic hematopoietic stem cell transplantation(allo-HSCT),and cellular immunotherapy while minimizing damage to the recipient′s immune function.MST injects donor stem cells to form microchimerisms,exerting anti-tumor effects and avoiding the occurrence of graftversushost disease(GVHD).MST is used for the treatment of hematological malignancies,significantly improving the rate of complete remission(CR),overall survival(OS),and disease-free survival(DFS),promoting hematopoietic recovery,reducing the risk of infection,and avoiding the occurrence of GVHD.In order to better apply MST in clinical practice,this article reviews the mechanism of action,current clinical application status,and current challenges faced by MST.

关 键 词：微移植 造血干细胞 细胞免疫治疗 移植物抗宿主病 

分 类 号：R457.7[医药卫生—治疗学]